Sudeep Pharma
NSE: SUDEEPPHRM · ISIN INE0QPI01025 · Healthcare
₹1,210.90−1.10 (−0.09%)
Monday 9 November, 13:16 IST. Delayed. Source: Yahoo Finance.
Price chart
₹1,210.90 −1.10 (−0.09%) today
The day
- Previous close
- ₹1,212.00
- Open
- ₹1,193.70
- Day high
- ₹1,231.40
- Day low
- ₹1,190.00
Listed on NSE since 28 November 2025.
Key numbers
- Market value
- ₹13,732 Cr
- P/E (trailing)
- 74.22
- EPS (trailing)
- ₹16.38
- Price to book
- 14.24
- Dividend yield
- 0.12%
- Return on equity
- 22.0%
- Debt to equity
- 0.19
- Profit margin
- 26.5%
- Volume today
- 1.27 L
- Average volume
- 2.83 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹426.17 Cr | ₹62.32 Cr |
| FY24 | ₹454.67 Cr | ₹133.19 Cr |
| FY25 | ₹497.41 Cr | ₹138.73 Cr |
| FY26 | ₹638.80 Cr | ₹172.89 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹197 Cr | ₹52 Cr | +13.3% |
| Q1 FY27Apr–Jun 2026 | ₹158 Cr | ₹41 Cr | – |
| Q4 FY26Jan–Mar 2026Audited | ₹182 Cr | ₹49 Cr | – |
| Q3 FY26Oct–Dec 2025 | ₹172 Cr | ₹-2 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹163 Cr | ₹46 Cr | – |
Source: Sudeep Pharma’s results filed with NSE, consolidated (the whole group). Net profit is the share of Sudeep Pharma’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹454 Cr | ₹402 Cr |
| Investments | ₹0 | ₹0 |
| Inventories | ₹275 Cr | ₹216 Cr |
| Owed by customers | ₹246 Cr | ₹228 Cr |
| Cash and equivalents | ₹54 Cr | ₹27 Cr |
| Total assets | ₹1,329 Cr | ₹1,175 Cr |
| Borrowings | ₹188 Cr | ₹148 Cr |
| Total liabilities | ₹356 Cr | ₹277 Cr |
| Shareholders’ equity | ₹957 Cr | ₹883 Cr |
Source: Sudeep Pharma’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Sudeep Pharma
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in India, the United States, and internationally. The company provides mineral salts, such as iron, calcium, sodium, zinc, copper, magnesium, manganese, potassium, picolinates, simethicone, and others;It also offers micronutrient premixes and liposomal, encapsulated ingredients, spray-dried formats, granulated ingredients, and triturated for sports nutrition, medical and clinical nutrition, infant nutrition, beverages, fortified staples, functional foods, and dairy products. In addition, the company provides a range of mineral powders and granules for carbonated, non-carbonated, and nutraceutical beverages; tricalcium phosphate, dicalcium phophate, dipotassium phosphate, ferric pyrophosphate, and disodium phosphate. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Vadodara
- Employees
- 525
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Sudeep Pharma in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 1.50 Per Share
Dividend · ex-date 23 July 2026
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.